2. Academic Validation
  3. The novel immunocompetent Eµ-SOX11CCND1 mouse model phenotypically and molecularly resembles human mantle cell lymphoma

The novel immunocompetent Eµ-SOX11CCND1 mouse model phenotypically and molecularly resembles human mantle cell lymphoma

  • Clin Cancer Res. 2025 Aug 26. doi: 10.1158/1078-0432.CCR-25-0534.
Hedieh Jafari 1,  Fiona Brown-Burke 2,  Betsy Pray 3,  Shelby Sloan 4,  JoBeth Helmig-Mason 4,  Ian Hout 5,  Sydney Leon 5,  Mackenzie Long 6,  Wing Keung Chan 4,  Walter Hanel 4,  Kara Corps 5,  Violetta V Leshchenko 7,  Donna Edwards 8,  Ravi Prakash Shukla 8,  Sidorela Reci 8,  Kris Vaddi 9,  Peggy Scherle 10,  Paul Collier 11,  Alessandro La Ferlita 4,  Satishkumar Singh 3,  Rosario Distefano 3,  Rosa Lapalombella 4,  Lalit Sehgal 3,  Robert B Faryabi 12,  Cem Meydan 13,  Christopher E Mason 13,  Robert A Baiocchi 4,  Samir Parekh 7,  Lapo Alinari 4
Affiliations

Affiliations

  • 1 The Ohio State University, Ohio, United States.
  • 2 German Cancer Research Center, Heidelberg, Germany.
  • 3 The Ohio State University, Columbus, Ohio, United States.
  • 4 The Ohio State University, Columbus, OH, United States.
  • 5 The Ohio State University, United States.
  • 6 University of Georgia, Columbus, United States.
  • 7 Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • 8 Icahn School of Medicine at Mount Sinai, United States.
  • 9 Prelude Therapeutics Incorporated, Wilmington, Delaware, United States.
  • 10 Prelude Therapeutics Incorporated, Wilmington, DE, United States.
  • 11 Weill Cornell Medicine, United States.
  • 12 University of Pennsylvania, Philadelphia, PA, United States.
  • 13 Weill Cornell Medicine, New York, NY, United States.
PMID: 40857109 DOI: 10.1158/1078-0432.CCR-25-0534
Abstract

Purpose: Mantle cell lymphoma (MCL) remains incurable despite therapeutic advances, highlighting the need for improved preclinical models. Existing transgenic MCL mouse models have significant limitations, restricting their translational value.

Experimental design: We generated an immunocompetent MCL model by overexpressing the key oncogenic drivers SOX11 and CCND1 under the Eµ enhancer in C57BL/6 mice, aiming to replicate human MCL's biological and pathological features.

Results: Eµ-SOX11CCND1 mice developed lymphoma marked by clonal B1a cell expansion in lymphatic and extranodal tissues. Morphologic, immunophenotypic, and transcriptional profiling revealed strong similarity to human MCL, with pathway analysis confirming significant molecular overlap. Importantly, lymphoma cells could be adoptively transferred into wild-type recipients, enabling therapeutic testing within an intact immune system.

Conclusions: The Eµ-SOX11CCND1 mouse represents a robust and biologically relevant model that faithfully recapitulates human MCL. Its immunocompetent nature and adoptive transfer capability make it a valuable model for studying disease mechanisms and evaluating novel therapeutic approaches for MCL patients.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z